FDA Approves Asmanex Twisthaler for Asthma
Asmanex Twisthaler contains mometasone furoate, a corticosteroid demonstrating potent antiinflammatory activity. Asmanex Twisthaler is indicated for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older, and is also the only inhaled asthma controller therapy approved for once daily initiation and management of asthma in patients previously treated with bronchodilators alone or inhaled corticosteroids.Posted: March 2005
Related Articles:
- FDA Approves Asmanex Twisthaler (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 - February 4, 2008
